17,261 trials
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 476; 496; 506; 1002 Participants
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 812; 794; 805; 1599 Participants
Psoriasis
Primary: Number of Treatment of Emergent Adverse Events — 2; 4; 2; 1 Participants
Melanoma
Primary: Median Overall Survival Response to Abraxane Plus Ipilimumab Therapy — 24.9 months
Psoriasis
Primary: Change in Target Lesion Individual Component Scores for Erythema, Scaling and Thickness Compared to Baseline — -0.5; -0.5; -0.8; -1.0 Scores on a scale
Dry Eye Syndrome
Primary: Change From Baseline in Schirmer I Test (Without Anesthesia) vs Week 4 - Full Analysis Set — 2.60; 3.99; 1.68 mm — p=0.078
Lung Adenocarcinoma · Lung Cancer · Lung Cancer Metastatic
Primary: Participants Response Rate — 11; 4; 8; 1 participants
Medulloblastoma · Neuroectodermal Tumor
Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927
Ovarian Cancer · Peritoneal Neoplasms · Fallopian Tube Cancer
Primary: Dose Limiting Toxicity (DLT) — 2; 3; 4 Dose Limiting Toxicities
Depressive Disorder, Major
Primary: Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -12.3; -12.2; -15.0; -14.7 score on a scale — p=0.724
Hepatic Cirrhosis · Liver Fibrosis
Primary: The Number of Participants Who Achieve ≥ 1 Stage Improvement in Liver Fibrosis (METAVIR Score) as Determined by Liver Biopsy After 12 Weeks of Treatment — 3; 6; 2…
Relapsed Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…
COVID-19
Primary: Time to Participant Recovery — 6; 12 days
HSV-2
Primary: Efficacy of 4 Different Doses of AIC316 and Matching Placebo With Respect to the Suppression of Herpes Simplex Virus Replication (Shedding Rate) — 21.2; 9.2; 2.0; 5.2…
Estrogen Levels Among Breast Cancer Patients
Primary: Changes in Serum Estradiol — 3.9 pg/mL